Phase
Condition
Neoplasms
Treatment
KQB365
Cetuximab
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
PART 1 (monotherapy): Histologically confirmed diagnosis of a solid tumor malignancywith either a KRAS G12C or KRAS G12S mutation.
PART 1 (combo therapy) & PART 2: Histologically confirmed diagnosis ofadenocarcinoma of the colon or rectum with either a KRAS G12C or KRAS G12S mutation.
Unresectable or metastatic disease
No available treatment with curative intent
Adequate organ function
Measurable disease per RECIST v1.1
Exclusion
Exclusion Criteria:
Active primary central nervous system tumors
Cardiac abnormalities
Active interstitial lung disease
Study Design
Connect with a study center
Mayo Clinic, Phoenix
Phoenix, Arizona 85054
United StatesActive - Recruiting
Sarah Cannon Cancer Institute at HealthONE
Denver, Colorado 80218
United StatesActive - Recruiting
Mayo Clinic, Jacksonville
Jacksonville, Florida 32224
United StatesActive - Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts 02215
United StatesActive - Recruiting
START Midwest
Grand Rapids, Michigan 49546
United StatesActive - Recruiting
Mayo Clinic, Rochester
Rochester, Minnesota 55905
United StatesActive - Recruiting
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio 44195
United StatesActive - Recruiting
NEXT Oncology
San Antonio, Texas 78229
United StatesActive - Recruiting
NEXT Virginia, LLC
Fairfax, Virginia 22031
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.